BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
July 30, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia, Inc., today reported it has submitted a 510(k) for approval of its patented Morph® DNA™ Steerable Introducer Sheath with the FDA.
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
July 25, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
July 17, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
July 08, 2024 07:00 ET
|
BioCardia, Inc.
CellProthera, and BioCardia [Nasdaq: BCDA], today announce success from a collaborative Phase II trial of ProtheraCytes for the treatment of AMI.
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
June 07, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.
BioCardia Announces Reverse Stock Split
May 21, 2024 17:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
May 14, 2024 16:02 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
May 09, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
May 01, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
April 25, 2024 09:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...